Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089739 · ClinicalTrials.gov registry record
Immune Indicators of Uveitis
A clinical trial of Uveitis and Immunosuppression, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00089739: Completed study of Uveitis and Immunosuppression, sponsored by National Eye Institute (NEI).
NCT00089739 is a study of Uveitis and Immunosuppression that has completed, run by National Eye Institute (NEI). The registered enrollment target is 100 participants, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089739, a study of Uveitis and Immunosuppression, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision loss. The study will examine whether certain substances in the blood can predict a reactivation of disease before it occurs, and how therapy may influence the activity of these substances. Previous studies have found some possible markers called GITR (glucocorticoid induced TNF related family receptor), SOCS (suppressors of cytokine secretion), and interleukin-15. Markers such as these may help guide physicians in safely tapering medicines in uveitis patients. Patients 18 years of age and older with sight-threatening uveitis may be eligible for this study. Participants are slowly tapered off their medicines when their disease is stable and there is no evidence of significant inflammation. If the disease remains inactive during tapering, all drug therapy is eventually stopped. Patients have eye examinations about every 1 to 3 months when the disease is quiet and every 2 to 4 weeks during flare-ups. Blood samples are drawn 2 to 3 times a year. In addition, patients may have the following procedures if needed: * Eye photography: Eye drops are given to enlarge the pupils for a thorough eye examination, and a special camera is used to take photographs. * Fluorescein angiography: This test checks for abnormalities of eye blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken with a special camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible abnormalities.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-08-09 |
| Est. Completion | 2008-10-28 |
What the finished NCT00089739 record still lists
NCT00089739 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower).
The record links to 5 conditions, with Uveitis appearing as the primary indexed condition, and to 0 interventions.
NCT00089739 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00089739 about?
NCT00089739 is a clinical study titled "Immune Indicators of Uveitis". This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision loss. The study will examine whether certain substances in the blood can predict a reactivation of d...
What is the current status of trial NCT00089739?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2004-08-09. Estimated completion is 2008-10-28.
What conditions does trial NCT00089739 study?
This clinical trial studies the following conditions: Uveitis, Immunosuppression, GITR, GITR Ligand, Suppressor of Cytokine Secretion.
Who is sponsoring clinical trial NCT00089739?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00089739 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00089739's enrollment target sits among peer trials
100 11th of 19 higher than 7 of 19 other Uveitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI